Killestein J - Search Results

1

IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis.

Lee LF, Axtell R, Tu GH, Logronio K, Dilley J, Yu J, Rickert M, Han B, Evering W, Walker MG, Shi J, de Jong BA, Killestein J, Polman CH, Steinman L, Lin JC. Lee LF, et al. Among authors: killestein j. Sci Transl Med. 2011 Jul 27;3(93):93ra68. doi: 10.1126/scitranslmed.3002400. Sci Transl Med. 2011. PMID: 21795588 Free PMC article.

2

MS functional composite: relation to disease phenotype and disability strata.

Kalkers NF, de Groot V, Lazeron RH, Killestein J, Adèr HJ, Barkhof F, Lankhorst GJ, Polman CH. Kalkers NF, et al. Among authors: killestein j. Neurology. 2000 Mar 28;54(6):1233-9. doi: 10.1212/wnl.54.6.1233. Neurology. 2000. PMID: 10746590

3

Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?

van Boxel-Dezaire AH, van Trigt-Hoff SC, Killestein J, Schrijver HM, van Houwelingen JC, Polman CH, Nagelkerken L. van Boxel-Dezaire AH, et al. Among authors: killestein j. Ann Neurol. 2000 Sep;48(3):313-22. doi: 10.1002/1531-8249(200009)48:3<313::aid-ana5>3.3.co;2-0. Ann Neurol. 2000. PMID: 10976637

4

Is Chlamydia pneumoniae present in the central nervous system of multiple sclerosis patients?

Morré SA, De Groot CJ, Killestein J, Meijer CJ, Polman CH, Van der Valk P, Van den Brule AJ. Morré SA, et al. Among authors: killestein j. Ann Neurol. 2000 Sep;48(3):399. Ann Neurol. 2000. PMID: 10976651 No abstract available.

5

Quality of life during the first 6 months of interferon-beta treatment in patients with MS.

Arnoldus JH, Killestein J, Pfennings LE, Jelles B, Uitdehaag BM, Polman CH. Arnoldus JH, et al. Among authors: killestein j. Mult Scler. 2000 Oct;6(5):338-42. doi: 10.1177/135245850000600508. Mult Scler. 2000. PMID: 11064444 Clinical Trial.

6

Is Epstein-Barr virus present in the CNS of patients with MS?

Morré SA, van Beek J, De Groot CJ, Killestein J, Meijer CJ, Polman CH, van der Valk P, Middeldorp JM, van Den Brule AJ. Morré SA, et al. Among authors: killestein j. Neurology. 2001 Mar 13;56(5):692. doi: 10.1212/wnl.56.5.692. Neurology. 2001. PMID: 11245733 No abstract available.

7

Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease.

Killestein J, Den Drijver BF, Van der Graaff WL, Uitdehaag BM, Polman CH, Van Lier RA. Killestein J, et al. Mult Scler. 2001 Jun;7(3):145-50. doi: 10.1177/135245850100700302. Mult Scler. 2001. PMID: 11475436

8

Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cells.

Killestein J, Rep MH, Barkhof F, Roos MT, Adèr HJ, van Lier RA, Polman CH. Killestein J, et al. J Neuroimmunol. 2001 Aug 30;118(2):286-94. doi: 10.1016/s0165-5728(01)00346-0. J Neuroimmunol. 2001. PMID: 11498263 Clinical Trial.

9

Interleukin-12p40 genotype plays a role in the susceptibility to multiple sclerosis.

van Veen T, Crusius JB, Schrijver HM, Bouma G, Killestein J, van Winsen L, Salvador Peña A, Polman CH, Uitdehaag BM. van Veen T, et al. Among authors: killestein j. Ann Neurol. 2001 Aug;50(2):275. doi: 10.1002/ana.1107. Ann Neurol. 2001. PMID: 11506417 No abstract available.

10

TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS.

Killestein J, Kalkers NF, Meilof JF, Barkhof F, van Lier RA, Polman CH. Killestein J, et al. Neurology. 2001 Sep 25;57(6):1129-31. doi: 10.1212/wnl.57.6.1129. Neurology. 2001. PMID: 11571353

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

309 results

Search Page